البحث الشامل غير مفعل
تخطى إلى المحتوى الرئيسي

Hepatocellular Carcinoma (HCC)

"last update: 28 April 2024"  

- Clinical indicators for monitoring

▪️ For Screening 

   1-Abdominal and pelvic ultrasound. 

   2-Serum alpha -fetoprotein level. 

▪️ laboratory evaluation before each cycle of systemic treatment (monthly)     

    1- complete blood picture. 

    2-liver function tests (total serum bilirubin, serum albumin, SGPT and INR). 

    3-kideny function tests (serum creatinine, blood urea) 

➡️ Research gaps 

•  Systematic inclusion of cost-benefit analyses in clinical trial with collection of health economic analysis such as incremental cost effectiveness ratio in order to facilitate clinical decision-making. 

• Predictive biomarkers: response to specific systemic targeted therapies. 

•  Improve models for pre-clinical testing of novel drugs. 

• Search for tools to assess quality of life in clinical trials. 

•  Therapies to prevent dropouts in the waiting lists of liver transplantation and downstaging strategies. 

• Adjuvant therapy after curative treatments  

➡️Update of this guidline  

This guidline will be updated whenever there is new evidence.